By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Juventas Therapeutics, Inc. 

10265 Carnegie Avenue

Cleveland  Ohio  44106  U.S.A.
Phone: 216-445-0830 Fax: 216-445-6514


SEARCH JOBS


Industry
Biotechnology






Company News
Juventas Therapeutics, Inc. Presents Phase 2 Data At American Heart Association Scientific Sessions That Shows JVS-100 Is Safe, Potentially Effective In Patients With Critical Limb Ischemia 11/18/2014 10:27:32 AM
Juventas Therapeutics, Inc. Phase 2 Clinical Study Results To Be Presented At 2014 American Heart Association Scientific Sessions 11/12/2014 9:14:09 AM
Juventas Therapeutics, Inc. Strengthens Management Team With New Senior Vice President Of Finance And Operations 10/28/2014 8:54:40 AM
Juventas Therapeutics, Inc. Completes Enrollment Of Phase I/II RETRO-HF Trial And Demonstrates Safety For Retrograde Infusion Of JVS-100 In Patients With Heart Failure 8/12/2014 8:03:56 AM
Juventas Therapeutics, Inc. Strengthens Leadership Team By Adding Two Industry Veterans 7/24/2014 9:16:36 AM
Juventas Therapeutics, Inc. To Present At The JMP Securities 2014 Healthcare Conference On June 24 6/23/2014 8:28:11 AM
Juventas Therapeutics, Inc. Data Demonstrates Significant Structural, Clinically Meaningful Benefit In Patients With Advanced Heart Failure 5/19/2014 6:32:48 AM
Juventas Therapeutics, Inc. To Present Top-Line Interim Results From Phase 2 STOP-HF Trial In Late-Breaking Oral Presentation At European Society of Cardiology Heart Failure Congress 5/6/2014 8:19:26 AM
Juventas Therapeutics, Inc. Completes Enrollment of Phase II STOP-HF Study of JVS-100 in Patients With Symptomatic Heart Failure 10/28/2013 11:02:51 AM
Juventas Therapeutics, Inc. Hires Biotechnology Veteran Paul Resnick as Vice President of Business Development 1/28/2013 9:54:34 AM
12
//-->